自身免疫性疾病困扰着全球约10%的人群，因发病机制复杂，一直是药物研发领域的热点之一。目前自身免疫性疾病的治疗主要包括激素、免疫抑制剂、免疫调节剂、抗炎药物等传统的合成抗风湿药（DMARDs)，大分子单克隆抗体或其衍生物如英夫利昔单抗、托珠单抗等生物DMARDs，JAK抑制剂如托法替尼、巴瑞特尼等等小分子靶向DMARDs。这类疾病的治疗通常需要数月甚至数年，药物不良反应的监测非常重要，不论是传统的DMARDs还是新型的生物或靶向DMARDs。天然类药物由于靶点广泛、安全性好，以及在免疫调节方面的潜在作用，如姜黄素、白藜芦醇、火把花根等制剂，在临床前或临床研究中显示了其在自身免疫性疾病治疗中的良好开发前景。

Autoimmune diseases, affecting about 10% of the world's population, have been one of the hotspots in the field of drug research because of their complex pathogenesis. The treatments for autoimmune diseases mainly include traditional synthetic disease-modifying antirheumatic drugs (DMARDs) such as glucocorticoids, immunosuppressants, immunomodulators, and anti-inflammatory drugs, macromolecular monoclonal antibodies or their derivatives such as Infliximab and Tolizumab, and small molecule targeted DMARDs such as JAK inhibitors Tofacitinib and Baritinib. The treatment of these diseases usually takes months or even years. Thus, adverse drug reaction monitoring is very important, regardless of whether they are traditional DMARDs or new biological DMARDs. For their wide range of targets, good safety, and potential role in immune regulation, natural drugs such as curcumin, resveratrol, and colquhounia root have shown good potential in the treatment of autoimmune diseases in preclinical or clinical studies.

利益冲突　所有作者声明不存在利益冲突